Description

Lucentis Solution for Injections 10 mg/ml. 0.23 ml. Vial (1 Needle)

Ingredients:

Lucentis contains ranibizumab as the active ingredient. Each milliliter of Lucentis solution for injection contains 10 mg of ranibizumab.

Dosage:

The usual dose of Lucentis is 0.5 mg (0.05 ml) injected into the eye once a month. Your healthcare provider will determine the appropriate dose and dosing schedule for your condition.

Indications:

Lucentis is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. It works by inhibiting the growth of abnormal blood vessels in the eye.

Contraindications:

Do not use Lucentis if you are allergic to ranibizumab or any of the ingredients in the product. Inform your healthcare provider about all your medical conditions and medications before starting Lucentis.

Directions:

Lucentis is administered by a healthcare professional as an injection into the eye. Follow your healthcare provider’s instructions carefully. Report any side effects or changes in your vision immediately.

Scientific Evidence:

Lucentis has been extensively studied in clinical trials for its efficacy in treating various retinal conditions. Research published in the New England Journal of Medicine has shown that Lucentis is highly effective in improving visual acuity and reducing retinal thickness in patients with AMD.

Additional Information:

It is important to attend all scheduled appointments for Lucentis injections to ensure the best treatment outcomes. Your healthcare provider will monitor your progress and adjust your treatment plan as needed. If you have any questions or concerns about Lucentis, do not hesitate to discuss them with your healthcare provider.

Pharmacological Effects: Lucentis is a recombinant humanized monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, Lucentis helps reduce abnormal blood vessel growth and leakage in the eye, thereby improving vision and reducing retinal damage.

Clinical Trials: Clinical trials have demonstrated the efficacy of Lucentis in improving visual acuity and retinal morphology in patients with various retinal diseases. A study published in Ophthalmology showed that Lucentis injections led to significant improvements in visual acuity and central retinal thickness in patients with diabetic macular edema.